Austria-based ImageBiopsy Lab has partnered with Danish company Radiobotics to implement artificial intelligence (AI) assisted disease diagnostics in the Germany, Austria, and Switzerland (DACH) region.
The use of AI in assisting disease diagnostics has increased in recent years. According to a report by GlobalData, the AI market will be worth $93bn this year. The analysis also identifies AI-assisted radiology as an emerging and disruptive technology that should be tracked closely, with Dutch conglomerate Philips being one of the leading patent filers in AI-assisted CT imaging.
According to ImageBiopsy Lab and Radiobotics, their AI-assisted technology will support disease diagnosis in musculoskeletal, orthopaedic, and trauma use cases. The technology is expected to reduce the manual interpretation of X-rays and MRI images, thereby increasing efficiency.
The technology will analyse imaging and conduct any measurement and scoring to help in interpretation and reduce manual load. It could also help with fracture detection workflow.
“Before even considering the use of AI, it’s crucial to grasp physicians’ diagnostic workflow and needs,” said ImageBiopsy Lab CEO Dr Richard Ljuhar.
“For this purpose, we’ve closely collaborated with leading musculoskeletal radiologists, orthopaedics, and traumatologists over the past years.”
ImageBiopsy has a US Food and Drug Administration (FDA)-approved radiological image processing software, IB Lab LAMA. It provides limb and angle measurements on leg X-rays, which can used by orthopaedic surgeons to manage their patients.
The other products in the company’s catalogue include IB Lab KOALA, which can detect signs of knee osteoarthritis using joint measurements; and IB Lab SQUIRREL module for scoliosis assessment.
Radiobotics has a fracture detection AI software, RBfracture, which highlights the possible fracture locations in each X-ray therapy, thereby reducing the time to analyse, especially in trauma settings.